Rhodiola rosea and its neuropsychotropic effects

Česká verze

Authors: Jan Juřica; Tereza Koupá
Authors place of work: Psychiatrická klinika FN, Brno ; Farmakologický ústav LF MU, Biochemický ústav PřF MU
Published in the journal: Čes. slov. Farm., 2016; 65, 87-93
Category: Přehledy a odborná sdělení

Summary

The paper reviews the neuropsychotropic effects of Rhodiola rosea, a succulent perennial plant which is native to dry, high-altitude regions of the northern hemisphere. The most valued part of the plant is its rhizome, which has a rose-like fragrance. In the available literature, there is a large number of mentions of its healing properties; nonetheless, only few of them are based on reliable scientific evidence. Of the neuropsychotropic effects, there are mentions of anxiolytic, antidepressant, neuroprotective and pro- cognitive properties and nonspecific „adaptogenic“ effects. These effects are well established according to the preclinical studies; nonetheless many of clinical studies have serious drawbacks in design or interpretation of results. Extracts of R. rosea are well tolerated in general and thus regarded as safe. On the other hand, some pharmacokinetic interactions at the level of cytochrome P450 enzymes cannot be omitted. The extracts of R. rosea, are considered, according to the regulation of the Ministry of Health, as food supplements. According to the long standing use of R. rosea, it may be used for traditional treatment of symptoms of fatigue or mental weakness, but it seems that there is not enough evidence for general recommendation of use of R. rosea extracts in clinical practice.

Key words:
Rhodiola rosea • neuropsychotropic effects • phytomedicine

Zdroje

1. Majewska A., Grazyna H., Miroslawa F., Natalia U., Agnieszka P., Alicja Z., Kuras M. Antiproliferative and antimitotic effect, S phase accumulation and induction of apoptosis and necrosis after treatment of extract from Rhodiola rosea rhizomes on HL-60 cells. J. Ethnopharmacol. 2006; 103(1): 43–52.

2. Shevtsov V., Zholus B., Shervarly V., Vol’skij V. B., Korovin Y. P., Khristich M. P., Roslyakova N. A., Wikman G. A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work. Phytomedicine 2003; 10(2-3): 95–105.

3. De Sanctis R., De Bellis R., Scesa C., Mancini U., Cucchiarini L., Dacha M. In vitro protective effect of Rhodiola rosea extract against hypochlorous acid-induced oxidative damage in human erythrocytes. Biofactors 2004; 20(3): 147–159.

4. Wojcik R., Siwicki A. K., Skopinska-Rozewska E., Mscisz A., Mielcarek S., Furmanowa M., Mrozikiewicz P. M. The in vitro influence of Rhodiola quadrifida extracts on non-specific cellular immunity in pigs. Cent. Eur. J. Immunol. 2008; 33(4): 193–196.

5. Niu C. S., Chen L. J., Niu H-S. Antihyperglycemic action of rhodiola-aqeous extract in type1-like diabetic rats. Bmc BMC Complement. Altern. Med. 2014; 14.

6. Khanum F., Bawa A. S., Singh B. Rhodiola rosea: a versatile adaptogen. Comprehensive Rev. Food Sci. Food Safety 2005; 4(3): 55–62.

7. Pooja B. A, Khanum F. Anti-inflammatory activity of Rhodiola rosea – a second-generation adaptogen. Phytother. Res. 2009; 23(8): 1099–1102.

8. De Bock K., Eijnde B. O., Ramaekers M., Hespel M. Acute Rhodiola rosea intake can improve endurance exercise performance. Int. J. Sport Nutr. Exerc. Metab. 2004; 14(3): 298–307.

9. Fintelmann V., Gruenwald J. Efficacy and tolerability of a Rhodiola rosea extract in adults with physical and cognitive deficiencies. Adv. Ther. 2007; 24(4): 929–939.

10. Zhang S., Chen X., Yang Y., Zhou X., Liu J., Ding F. Neuroprotection against cobalt chloride-induced cell apoptosis of primary cultured cortical neurons by salidroside. Mol. Cell. Biochem. 2011; 354(1–2): 161–170.

11. Chen X., Zhang Q., Cheng Q., Tang J. Y., Qin Y. J., Chung P., Wong R., Hagg U. Protective effect of salidroside against H2O2- -induced cell apoptosis in primary culture of rat hippocampal neurons. Molecular and Cellular Biochemistry 2009; 332(1–2): 85–93.

12. EMA. Assessment report on Rhodiola rosea L., rhizoma et radix. In: HMPC (ed.) European Medicines Agency, 2012: 1–33.

13. Panossian A., Wikman G., Sarris J. Rosenroot (Rhodiola rosea): Traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine 2010; 17(7): 481–493.

14. Hoškovec L. Rhodiola rosea L. – rozchodnice růžová/rozchodnica ružová, 2007. http://botany.cz/cs/rhodiola-rosea/

15. Potužák M. Nové nebo méně známé rostliny: Rhodiola rosea L. Čas. čes. Lékárníků 2008; (9): 24–25.

16. Kucinskaite A., Pobłocka-Olech L., Krauze-Baranowska M., Sznitowska M., Savickas A., Briedis V. Evaluation of biologically active compounds in roots and rhizomes of Rhodiola rosea L. cultivated in Lithuania. Medicina 2007; 43(6): 487–494.

17. Galambosi B., Galambosi Z., Hethelyi E., Szoeke E., Volodin V., Poletaeva I., Iljina I. Importance and quality of roseroot (Rhodiola rosea L.) growing in the European North. Zeitschrift Fur Arznei- & Gewurzpflanzen 2010; 15(4): 160–169.

18. Rohloff J. Volatiles from rhizomes of Rhodiola rosea L. Phytochemistry 2002; 59(6): 655–661.

19. Evstatieva L., Todorova M., Antonova D., Staneva J. Chemical composition of the essential oils of Rhodiola rosea L. of three different origins. Pharmacognosy Magazine 2010; 6(24): 256–258.

20. Anilakumar P. K. R., Khanum F., Bawa A. S. Phytoconstituents and antioxidant potency of Rhodiola rosea – A versatile adaptogen. J. Food. Biochem. 2006; 30(2): 203–214.

21. Grace M. H., Yousef G. G., Kurmukov A. G., Raskin I., Lila M. A. Phytochemical Characterization of an Adaptogenic Preparation from Rhodiola heterodonta. Nat. Prod. Commun. 2009; 4(8): 1053–1058.

22. Chan S-W. Panax ginseng, Rhodiola rosea and Schisandra chinensis. International J. Food Sci. Nut. 2012; 63: 75–81.

23. Chiang H. M., Chen H. C., Wu C. S., Wu P. Y., Wen K. C. Rhodiola plants: Chemistry and biological activity. J. Food Drug Anal. 2015; 23(3): 359–369.

24. Jafari M., Felgner J. S., Bussel I. I., Hutchili T., Khodayari B., Rose M. R., Vince-Cruz C. Mueller L. D. Rhodiola: A promising anti-aging Chinese Herb. Rejuvenation Res. 2007; 10(4): 587–602.

25. Kurkin V. A., Zapesochnaya G. G., Shchavlinsky A. N. Terpoenoids of Rhodiola rosea rhizomes. Him. Prir. Soedin. 1985(5): 632–636.

26. Kwon H. J., Ryu Y. B., Jeong H. J., Kim J. H., Park S. J., Chang J. S., Kim M., Rho M. C., Lee W. S. Rhodiosin, an Antioxidant Flavonol Glycoside from Rhodiola rosea. J. Korean Soc. Appl. Biol. Chem. 2009; 52(5): 486–492.

27. Panossian A., Wikman G. Traditional Use, Chemical Composition, Pharmacology, and Clinical Efficacy of Rhodiola rosea L. Pharm. Biol. 2010; 48: 6.

28. Shamseer L., Bukutu C., Vohra S. Rhodiola Rosea: State of the Clinical Evidence. Pharm. Biol. 2010; 48: 26.

29. van Diermen D., Marston A., Bravo J., Reist M., Carrupt P. A., Hostettmann K. Monoamine oxidase inhibition by Rhodiola rosea L. roots. J. Ethnopharmacol. 2009; 122(2): 397–401.

30. Chen Q. G., Zeng Y. S., Qu Z. Q., Tang J. Y., Qin Y. J., Chung P., Wong R., Hagg U. The effects of Rhodiola rosea extract on 5-HT level, cell proliferation and quantity of neurons at cerebral hippocampus of depressive rats. Phytomedicine 2009; 16(9): 830–838.

31. Yang S., Yu H., Kang D., Ma Z. Q., Qu R., Fu Q., Ma S. P. Antidepressant-like effects of salidroside on olfactory bulbectomy-induced pro-inflammatory cytokine production and hyperactivity of HPA axis in rats. Pharmacol. Biochem. Behav. 2014; 124: 451–457.

32. Perfumi M., Mattioli L. Adaptogenic and central nervous system effects of single doses of 3% rosavin and 1% salidroside Rhodiola rosea L. extract in mice. Phytotherapy Res. 2007; 21(1): 37–43.

33. Cayer C., Ahmed F., Filion V., Saleem A., Cuerrier A., Allard M., Rochefort G., Merali Z., Arnason J. T. Characterization of the Anxiolytic Activity of Nunavik Rhodiola rosea. Planta Med. 2013; 79(15): 1385–1391.

34. Cao L. L., Du G. H., Wang M. W. The effect of salidroside on cell damage induced by glutamate and intracellular free calcium in PC12 cells. J. Asian Nat. Prod. Res. 2006; 8(1–2): 159–165.

35. Yu S., Shen Y., Liu J. Involvement of ERK1/2 pathway in neuroprotection by salidroside against hydrogen peroxide-induced apoptotic cell death. J. Mol. Neurosci. 2010; 40(3): 321–331.

36. Yu S., Liu M., Gu X., Ding F. Neuroprotective effects of salidroside in the PC12 cell model exposed to hypoglycemia and serum limitation. Cell. Mol. Neurobiol. 2008; 28(8): 1067–1078.

37. Zhang W. S., Zhu L. Q., Niu F. L., Deng R. C., Ma C. X. Protective effects of salidroside on injury induced by hypoxia/hypoglycemia in cultured neurons. Zhongguo Zhong Yao Za Zhi 2004; 29(5): 459–462.

38. Zhang L., Yu H., Sun Y., Lin X., Chen B., Tan C., Cao G., Wang Z. Protective effects of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. Eur. J. Pharmacol. 2007; 564(1–3): 18–25.

39. Lee Y., Jung J., Jang S., Kim J., Ali Z. Khan I.A., Khan I. A. Oh S. Anti-Inflammatory and Neuroprotective Effects of Constituents Isolated from Rhodiola rosea. Evid. Based Complement. Alternat. Med. 2013.

40. Pogorelyĭ V. E., Makarova L. M. Rhodiola rosea extract for prophylaxis of ischemic cerebral circulation disorder]. Eksp. Klin. Farmakol. 2002; 65(4): 19–22.

41. Qu Z. Q., Zhou Y., Zeng Y. S., Li Y., Chung P. Pretreatment with Rhodiola Rosea Extract Reduces Cognitive Impairment Induced by Intracerebroventricular Streptozotocin in Rats: Implication of Anti-oxidative and Neuroprotective Effects. Biomed. Environ. Sci. 2009; 22(4): 318–326.

42. Zhang J., Zhen Y. F., Pu-Bu-Ci-Ren, Song L. G., Kong W. N., Shao T. M., Li X., Chai X. Q. Salidroside attenuates beta amyloid-induced cognitive deficits via modulating oxidative stress and inflammatory mediators in rat hippocampus. Behav. Brain Res. 2013; 244: 70–81.

43. Qu Z., Zhou Y., Zeng Y., Lin Y. K., Li Y., Zhong Z. Q., Chan W. Y. Protective Effects of a Rhodiola Crenulata Extract and Salidroside on Hippocampal Neurogenesis against Streptozotocin-Induced Neural Injury in the Rat. Plos One 2012; 7(1).

44. Wang H., Zhou G., Gao X., Yidan W., Wenbing Y. Acetylcholinesterase inhibitory-active components of Rhodiola rosea L. Food Chem. 2007; 105(1): 24–27.

45. Hillhouse B. J., Ming D. S., French C. J., Towers G. H. Acetylcholine esterase inhibitors in Rhodiola rosea. Pharm. Biol. 2004; 42(1): 68–72.

46. Mannucci C., Navarra M., Calzavara E., Caputi AP, Calapai G. Serotonin involvement in Rhodiola rosea attenuation of nicotine withdrawal signs in rats. Phytomedicine 2012; 19(12): 1117–1124.

47. Mattioli L., Perfumi M. Evaluation of Rhodiola rosea L. extract on affective and physical signs of nicotine withdrawal in mice. J. of Psychopharmacol. 2011; 25(3): 402–410.

48. Titomanlio F., Manzanedo C., Rodriguez-Arias M., Mattioli L., Perfumi M., Miñarro J., Aguilar M. A. Rhodiola rosea Impairs Acquisition and Expression of Conditioned Place Preference Induced by Cocaine. Evid. Based Complement. Alternat. Med. 2013.

49. Mattioli L., Titomanlio F., Perfumi M. Effects of a Rhodiola rosea L. extract on the acquisition, expression, extinction, and reinstatement of morphine-induced conditioned place preference in mice. Psychopharmacology 2012; 221(2): 183–193.

50. Titomanlio F., Perfumi M., Mattioli L. Rhodiola rosea L. extract and its active compound salidroside antagonized both induction and reinstatement of nicotine place preference in mice. Psychopharmacology 2014; 231(10): 2077–2086.

51. Panossian A., Nikoyan N., Ohanyan N., Hovhannisyan A., Abrahamyan H., Gabrielyan E., Wikman G. Comparative study of Rhodiola preparations on behaviorol despair of rats. Phytomedicine 2008; 15(1–2): 84–91.

52. Dimpfel W. Pharmacological classification of herbal extracts by means of comparison to spectral EEG signatures induced by synthetic drugs in the freely moving rat. J. Ethnopharmacol. 2013; 149(2): 583–589.

53. Darbinyan V., Aslanyan G., Amroyan E., Gabrielyan E., Malmström C., Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nordic J. of Psych. 2007; 61(5): 343–348.

54. EMA. Overview of comments received on Community herbal monograph on Rhodiola rosea L., rhizoma et radix. In: (HMPC) CoHMP (ed.) 2012: 1–21.

55. Bystritsky A., Kerwin L., Feusner J. D. A pilot study of Rhodiola rosea (Rhodax (R)) for generalized anxiety disorder (GAD). J. Altern. Complement. Med. 2008; 14(2): 175–180.

56. Cropley M., Banks A. P., Boyle J. The Effects of Rhodiola rosea L. Extract on Anxiety, Stress, Cognition and Other Mood Symptoms. Phytotherapy Res. 2015; 29(12): 1934–1939.

57. Mao J., Xie S., Zee J., et al. Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. Phytomedicine 2015; 22(3): 394–399.

58. Olsson E. M. G., von Scheele B., Panossian A. G. A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Standardised Extract SHR-5 of the Roots of Rhodiola rosea in the Treatment of Subjects with Stress-Related Fatigue. Planta Med. 2009; 75(2): 105–112.

59. Schutgens F. W., Neogi P., van Wijk E. P., van Wijk R., Wikman G., Wiegant F. A. The influence of adaptogens on ultraweak biophoton emission: a pilot-experiment. Phytother. Res. 2009; 23(8): 1103–1108.

60. Darbinyan V., Kteyan A., Panossian A., Gabrielian E., Wikman G., Wagner H. Rhodiola rosea in stress induced fatigue – A double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. Phytomedicine 2000; 7(5): 365–371.

61. Aslanyan G., Amroyan E., Gabrielyan E., Nylander M., Wikman G., Panossian A. Double-blind, placebo-controlled, randomised study of single dose effects of ADAPT-232 on cognitive functions. Phytomedicine 2010; 17(7): 494–499.

62. Ha Z., Zhu Y., Zhang X., Cui J., Zhang S., Ma Y., Wang W., Jian X. The effect of rhodiola and acetazolamide on the sleep architecture and blood oxygen saturation in men living at high altitude. Zhonghua Jie He He Hu Xi Za Zhi 2002; 25(9): 527–530.

63. Hellum B. H., Tosse A., Hoybakk K., Thomsen M., Rohloff J., Georg Nilsen O. Potent in vitro Inhibition of CYP3A4 and P-Glycoprotein by Rhodiola rosea. Planta Medica 2010; 76(4): 331–338.

64. Panossian A., Hovhannisyan A., Abrahamyan H., Gabrielyan E., Wikman G. Pharmacokinetic and Pharmacodynamic Study of Interaction of Rhodiola rosea SHR-5 Extract with Warfarin and Theophylline in Rats. Phytotherapy Res. 2009; 23(3): 351–357.

65. Xu W., Zhang T., Wang Z., et al. Two potent cytochrome P450 2D6 inhibitors found in Rhodiola rosea. Pharmazie 2013; 68(12): 974–976.